|
RAP2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.06969988422634E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.11080100252093E-11 |
| Normal-vs-Stage2 |
1.074580E-01 |
| Normal-vs-Stage3 |
1.58910000047641E-07 |
| Normal-vs-Stage4 |
4.75060000004746E-06 |
| Stage1-vs-Stage2 |
1.430230E-04 |
| Stage1-vs-Stage3 |
8.006200E-01 |
| Stage1-vs-Stage4 |
6.482600E-01 |
| Stage2-vs-Stage3 |
9.824900E-04 |
| Stage2-vs-Stage4 |
2.300900E-03 |
| Stage3-vs-Stage4 |
8.347600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.65489844050626E-11 |
| Normal-vs-AfricanAmerican |
4.523000E-03 |
| Normal-vs-Asian |
1.09579999996168E-06 |
| Caucasian-vs-AfricanAmerican |
8.436200E-01 |
| Caucasian-vs-Asian |
9.176200E-01 |
| AfricanAmerican-vs-Asian |
8.352800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.89830004230174E-09 |
| Normal-vs-Female |
1.03490005454177E-09 |
| Male-vs-Female |
2.925800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.03919983729384E-10 |
| Normal-vs-Age(41-60Yrs) |
1.13889999986405E-07 |
| Normal-vs-Age(61-80Yrs) |
1.754620E-04 |
| Normal-vs-Age(81-100Yrs) |
3.091700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.403800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.200400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.594600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.276000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.214430E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.315430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.516000E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
2.940600E-01 |
| Classical-VS-Normal |
1.62925228863742E-12 |
| Tall-VS-Follicular |
5.95829999783248E-08 |
| Tall-VS-Other |
1.711440E-01 |
| Tall-VS-Normal |
5.58380000015291E-07 |
| Follicular-VS-Other |
1.548170E-02 |
| Follicular-VS-Normal |
3.919400E-01 |
| Other-VS-Normal |
4.006200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.03599999999415E-05 |
| Normal-vs-N1 |
1.25390000005332E-06 |
| N0-vs-N1 |
2.580100E-02 |
|
|
